LTM1201LD

LTM1201LD is an experimental combination therapy for obstructive sleep apnea (OSA) that integrates pharmacological treatment with a mechanical device. It consists of **LTM1201L**—a fixed-dose combination of the norepinephrine reuptake inhibitor **atomoxetine** and the muscarinic antagonist **oxybutynin**—administered alongside a **dental appliance** (mandibular advancement device). The pharmacological component is designed to increase the activity of the hypoglossal motor nucleus and the genioglossus muscle during sleep, addressing the 'low muscle responsiveness' phenotype of OSA. The dental appliance provides mechanical stabilization of the upper airway. This multi-modal approach, developed at **Brigham and Women's Hospital**, aims to improve OSA severity by targeting both anatomical and non-anatomical (neuromuscular) traits of the disease.

Brand names

LTM1201LDLTM-1201LDLTM 1201LD

Other names

atomoxetine + oxybutynin + dental appliance